Advantage of inhaled corticosteroids as additional therapy to systemic corticosteroids for pediatric acute asthma exacerbations: a cost-effectiveness analysis

Simple item page
dc.contributor.authorCarlos E. Rodriguez-Martinez
dc.contributor.authorMonica P. Sossa-Briceño
dc.contributor.authorCastro Rodríguez, José Antonio
dc.date.accessioned2022-03-07T14:16:26Z
dc.date.available2022-03-07T14:16:26Z
dc.date.issued2020
dc.description.abstractObjective: Although the efficacy of systemic corticosteroids (SCs) in acute asthma exacerbations is well established, the fact that many children still require admission to hospital and that SCs have a slow onset of action are cause of concern. For this reason, the use of inhaled corticosteroids (ICS) as a therapy added to SCs has been explored, with no clarity about its cost-effectiveness. The aim of the present study was to evaluate the cost-effectiveness of ICS in addition to SCs (ICS + SCs) compared to standard therapy with SCs for treating pediatric asthma exacerbations. Methods: A decision-analysis model was developed to estimate the cost-effectiveness of SCs compared to ICS + SCs for treating pediatric patients with acute asthma exacerbations. Effectiveness parameters were obtained from a systematic review of the literature. Cost data obtained from hospital bills and from the national manual of drug prices. The study was carried out from the perspective of the national healthcare system in Colombia. The main outcome of the model was avoidance of hospital admission. Results: For the base-case analysis, the model showed that compared to SCs, therapy with ICS + SCs was associated with lower total costs (US$88.76 vs.US$97.71 average cost per patient) and a lower probability of hospital admission (0.9060 vs. 0.9000), thus showing dominance. Conclusions: This study shows that compared with standard therapy with SCs, ICS + SCs for treating pediatric patients with acute asthma exacerbations is the preferred strategy because it was associated with a lower probability of hospital admission, at lower total treatment costs.
dc.format.extent9 páginas
dc.fuente.origenORCID
dc.identifier.doi10.1080/02770903.2019.1628254
dc.identifier.doi10.1080/02770903.2019.1628254
dc.identifier.eissn1532-4303
dc.identifier.issn0277-0903
dc.identifier.urihttps://doi.org/10.1080/02770903.2019.1628254
dc.identifier.urihttps://www.doi.org/10.1080/02770903.2019.1628254
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/63309
dc.information.autorucEscuela de medicina ; Castro Rodríguez, José Antonio ; 0000-0002-0708-4281 ; 113247
dc.issue.numeroNo. 9
dc.language.isoen
dc.nota.accesoContenido parcial
dc.pagina.final958
dc.pagina.inicio949
dc.provenancepolivero 2022-03-07 11:16:25
dc.relation.isformatofJournal of Asthma, Vol. 57, No. 9 (Jun., 2019), pp. 949-958
dc.rightsacceso restringido
dc.subjectAsthma exacerbation
dc.subjectHealth economics
dc.subjectInhaled corticosteroid
dc.subjectAsthma exacerbation
dc.subjectHealth economics
dc.subjectInhaled corticosteroid
dc.subjectSystemic corticosteroid
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.otherMedicina y salud
dc.titleAdvantage of inhaled corticosteroids as additional therapy to systemic corticosteroids for pediatric acute asthma exacerbations: a cost-effectiveness analysis
dc.typeartículo
dc.volumenVol. 57
sipa.codpersvinculados113247
Files
Collections
Artículos de revistas